---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004419"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T19:38:13.947936+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences reports FY2021 net loss $35.3M; cash $149.1M into 2024

## Summary
- Net loss for FY2021 was $35.3M, up from $22.2M in FY2020; R&D expenses rose to $25.2M.
- Cash and equivalents totaled $149.1M at Dec 31, 2021; runway into 2024.
- On track to initiate pivotal trial in choroidal melanoma and Phase 1 in NMIBC in 2H 2022.
- European Commission granted Orphan Drug Designation for AU-011 in uveal melanoma.
- John Maraganore, former Alnylam CEO, joins as strategic advisor.

## SEC filing metadata
- accession: 0000950170-22-004419
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017022004419/0000950170-22-004419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017022004419/aura-20220323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004419
- JSON: https://secwatch.observer/filing/0000950170-22-004419.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.